Home/Pipeline/VTX958

VTX958

Inflammatory Bowel Disease (IBD)

Phase 2Completed

Key Facts

Indication

Inflammatory Bowel Disease (IBD)

Phase

Phase 2

Status

Completed

Company

Ventyx Biosciences

About Ventyx Biosciences

Ventyx Biosciences leverages expertise in medicinal chemistry, structural biology, and immunology to discover and develop differentiated oral therapeutics for diseases with high unmet need. Its clinical-stage pipeline is built around two core platforms: NLRP3 inflammasome inhibitors (with both peripheral and CNS-penetrant candidates) and immunomodulators for inflammatory bowel disease (S1P1R and TYK2). The company's strategic acquisition by Lilly in early 2026 validates its platform and provides significant resources to advance its programs.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases Neurodegenerative Diseases Cardiometabolic Diseases

Other Inflammatory Bowel Disease (IBD) Drugs

Drug	Company	Phase	Status
DFTX-201	Definium Therapeutics	Preclinical	Lead Optimization
COSMO-232	Cosmo Pharmaceuticals	Preclinical	Active
Tamuzimod	Ventyx Biosciences	Phase 2	Completed
GPR35 Agonist	Nxera Pharma	Preclinical	Active
SL-325	Shattuck Labs	Phase 2	Active
SL-425	Shattuck Labs	Phase 1	Active
ABS-101	AbSci	Pre-clinical	Active (Published research)
Metabolite Delivery Platform (Therapeutic Programs)	ClostraBio	Pre-clinical	Platform Development
ABO21009	AboleIIs Pharma	Phase 1	Planned/Preclinical